1-11 of 11
Authors: Sara Labiano
Journal Article
TMOD-07. DEVELOPMENT AND CHARACTERIZATION OF A SPINAL CORD DIFFUSE MIDLINE GLIOMA MODEL Free
Neuro-Oncology, Volume 26, Issue Supplement_8, November 2024, Page viii320, https://doi.org/10.1093/neuonc/noae165.1271
Published: 11 November 2024
Journal Article
The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models Open Access
Neuro-Oncology, Volume 26, Issue 8, August 2024, Pages 1509–1525, https://doi.org/10.1093/neuonc/noae066
Published: 30 March 2024
Journal Article
EXTH-58. UNRAVELING THE MECHANISMS UNDERLYING THE THERAPEUTIC EFFICACY OF TIM-3 BLOCKADE IN DIPGS Free
Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii222, https://doi.org/10.1093/neuonc/noac209.856
Published: 14 November 2022
Journal Article
DIPG-22. Modifying the tumor microenvironment with a TIM-3 monoclonal antibody as a therapeutic strategy for DIPGs Open Access
Neuro-Oncology, Volume 24, Issue Supplement_1, June 2022, Pages i22–i23, https://doi.org/10.1093/neuonc/noac079.079
Published: 03 June 2022
Journal Article
IMMU-18. Targeting Antigen Presenting Cells to improve virotherapy efficacy in Diffuse Midline Gliomas Open Access
Neuro-Oncology, Volume 24, Issue Supplement_1, June 2022, Page i85, https://doi.org/10.1093/neuonc/noac079.311
Published: 03 June 2022
Journal Article
IMMU-09. MODULATING THE MYELOID POPULATION IN DIPG MODELS WITH ONCOLYTIC VIRUS AND COMPLEMENT INHIBITORS SHOWS THERAPEUTIC EFFICACY Open Access
Neuro-Oncology, Volume 23, Issue Supplement_1, June 2021, Pages i28–i29, https://doi.org/10.1093/neuonc/noab090.117
Published: 01 June 2021
Journal Article
IMMU-08. MICROENVIRONMENT MODULATION BY TIM-3 BLOCKADE IMPROVES THE OUTCOME OF PRECLINICAL DIPG MODELS Open Access
Neuro-Oncology, Volume 23, Issue Supplement_1, June 2021, Page i28, https://doi.org/10.1093/neuonc/noab090.116
Published: 01 June 2021
Journal Article
IMMU-06. DELTA-24-RGD EXPRESSING POSITIVE IMMUNE MODULATORS SHOW ANTI-DIPG EFFECT AND INCREASE TUMOR IMMUNE INFILTRATION Open Access
Neuro-Oncology, Volume 23, Issue Supplement_1, June 2021, Page i28, https://doi.org/10.1093/neuonc/noab090.114
Published: 01 June 2021
Journal Article
IMMU-01. THE ONCOLYTIC VIRUS DELTA-24-RGD IN COMBINATION WITH AN AGONISTIC CD40 MAB INDUCES A DURABLE AND SYNERGISTIC ANTI-TUMOR IMMUNE EFFECT IN DIPG PRECLINICAL MODELS Open Access
Neuro-Oncology, Volume 23, Issue Supplement_1, June 2021, Pages i26–i27, https://doi.org/10.1093/neuonc/noab090.109
Published: 01 June 2021
Journal Article
IMMU-14. ONCOLYTIC ADENOVIRUS DELTA-24-RGD ENGINEERED TO EXPRESS 4-1BBL AS A THERAPEUTIC APPROACH FOR DIPG Free
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii107, https://doi.org/10.1093/neuonc/noaa215.444
Published: 09 November 2020
Journal Article
IMMU-21. THE COMBINATION OF DELTA-24-ACT WITH AN IMMUNE CHECKPOINT INHIBITOR RESULTS IN ANTI-GLIOMA EFFECT AND IMMUNE MEMORY Free
Neuro-Oncology, Volume 22, Issue Supplement_2, November 2020, Page ii109, https://doi.org/10.1093/neuonc/noaa215.451
Published: 09 November 2020
